nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Advanced forms of MPNs are accompanied by chromosomal abnormalities that lead to dysregulation of TP53
|
Marcellino, Bridget K. |
|
|
2 |
24 |
p. 3581-3589 |
artikel |
2 |
A locus on chromosome 5 shows African ancestry–limited association with alloimmunization in sickle cell disease
|
Williams, Lesedi M. |
|
|
2 |
24 |
p. 3637-3647 |
artikel |
3 |
A second-generation TKI should always be used as initial therapy for CML
|
Cortes, Jorge E. |
|
|
2 |
24 |
p. 3653-3655 |
artikel |
4 |
Depletion of murine fetal hematopoietic stem cells with c-Kit receptor and CD47 blockade improves neonatal engraftment
|
Witt, Russell G. |
|
|
2 |
24 |
p. 3602-3607 |
artikel |
5 |
Editorial Board
|
|
|
|
2 |
24 |
p. i |
artikel |
6 |
HLA epitope mismatch in haploidentical transplantation is associated with decreased relapse and delayed engraftment
|
Rimando, Joseph |
|
|
2 |
24 |
p. 3590-3601 |
artikel |
7 |
Imatinib is still recommended for frontline therapy for CML
|
Hantel, Andrew |
|
|
2 |
24 |
p. 3648-3652 |
artikel |
8 |
Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL
|
Kater, Arnon P. |
|
|
2 |
24 |
p. 3566-3571 |
artikel |
9 |
Platelet-specific deletion of SNAP23 ablates granule secretion, substantially inhibiting arterial and venous thrombosis in mice
|
Williams, Christopher M. |
|
|
2 |
24 |
p. 3627-3636 |
artikel |
10 |
Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance)
|
Roboz, Gail J. |
|
|
2 |
24 |
p. 3608-3617 |
artikel |
11 |
Safety and efficacy of an oncolytic viral strategy using bortezomib with ICE/R in relapsed/refractory HIV-positive lymphomas
|
Reid, Erin G. |
|
|
2 |
24 |
p. 3618-3626 |
artikel |
12 |
Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms
|
Rampal, Raajit K. |
|
|
2 |
24 |
p. 3572-3580 |
artikel |